Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Laura V. Stampleman, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Leonard M Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2014) 124 (21): 4774.

https://doi.org/10.1182/blood.V124.21.4774.4774

Published: 2014

Journal Articles

Serum B-Cell Maturation Antigen Is a Novel Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival

Michael Ghermezi, Suzie Vardanyan, MS, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Claudia Andreu-Vieyra, Eric Sanchez, BA, Regina A. Swift, RN, James R. Berenson, MD

Blood (2014) 124 (21): 3405.

https://doi.org/10.1182/blood.V124.21.3405.3405

Published: 2014

Journal Articles

Lack of Significance of ISS Staging and Depth of Response in Predicting Overall Survival for Multiple Myeloma Patients

Ariana Berenson, Suzie Vardanyan, MS, Michael Ghermezi, Nika M Harutyunyan, Jillian Gottlieb, Ran Halleluyan, Claudia Andreu-Vieyra, Regina A. Swift, RN, James R. Berenson, MD

Blood (2014) 124 (21): 5771.

https://doi.org/10.1182/blood.V124.21.5771.5771

Published: 2014

Journal Articles

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard Klein, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2013) 122 (21): 3218.

https://doi.org/10.1182/blood.V122.21.3218.3218

Published: 2013

Journal Articles

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

James R. Berenson, MD, James D. Hilger, Ph.D., Robert Dichmann, MD, Dipti Patel-Donnelly, MD, Ralph V. Boccia, MD, Alberto Bessudo, MD, Laura V. Stampleman, MD, Donald S. Gravenor, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2012) 120 (21): 4063.

https://doi.org/10.1182/blood.V120.21.4063.4063

Published: 2012

Journal Articles

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard M. Klein, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2012) 120 (21): 2979.

https://doi.org/10.1182/blood.V120.21.2979.2979

Published: 2012

Journal Articles

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph V. Boccia, MD, Stephen J. Noga, MD, PhD, Donald S. Gravenor, MD, Dipti Patel-Donnelly, MD, Robert S. Siegel, MD, Tarun Kewalramani, MD, Edward J. Gorak, DO, MS, Regina A. Swift, RN, Debra Mayo, PharmD, MHA

Blood (2011) 118 (21): 1857.

https://doi.org/10.1182/blood.V118.21.1857.1857

Published: 2011

Journal Articles

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph Boccia, MD, Donald S. Gravenor, MD, Stephen J. Noga, MD, PhD, Robert S Siegel, MD, Regina A. Swift, RN, Michael D Ehrman, MS, Debra Bensen-Kennedy, MD

Blood (2010) 116 (21): 3057.

https://doi.org/10.1182/blood.V116.21.3057.3057

Published: 2010

Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)

James R. Berenson, MD, Ori Yellin, MD, Alan D. Cartmell, MD, Thomas B. S. Woliver, MD, Marshall S. Flam, MD, Youram Nassir, MD, Robert Vescio, MD, Regina A. Swift, RN

Blood (2010) 116 (21): 3044.

https://doi.org/10.1182/blood.V116.21.3044.3044

Published: 2010

Journal Articles

A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Youram Nassir, MD, Shellie Rothstein, Regina A. Swift

Blood (2009) 114 (22): 1855.

https://doi.org/10.1182/blood.V114.22.1855.1855

Published: 2009

Journal Articles

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

James R. Berenson, MD, Ori Yellin, MD, Ravi Patel, MD, Chien-Shing Chen, MD, Ralph Vincent Boccia, MD, Donald Colbourn, MD, Honghao (Hank) Yang, MD, PhD, Varun Gupta, MD, George F. Geils, Jr., MD, Youram Nassir, MD, Jacqueline Hilger, MS, Regina A. Swift

Blood (2009) 114 (22): 4936.

https://doi.org/10.1182/blood.V114.22.4936.4936

Published: 2009

Journal Articles

A Randomized Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices.

James R. Berenson, MD, David J. Donahue, Ori Yellin, MD, Gargi Upadhyaya, MD, Youram Nassir, MD, Regina A. Swift

Blood (2009) 114 (22): 4234.

https://doi.org/10.1182/blood.V114.22.4234.4234

Published: 2009

Journal Articles

Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

James R. Berenson, MD, Ori Yellin, MD, Donald Woytowitz, MD, Marshall S. Flam, MD, Alan Cartmell, MD, Ravi Patel, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 3602.

https://doi.org/10.1182/blood.V110.11.3602.3602

Published: 2007

Journal Articles

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Marshall S. Flam, MD, Siu-Fun Wong, PharmD, Olcay Batuman, MD, Mehdi M. Moezi, MD, Donald Woytowitz, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 3606.

https://doi.org/10.1182/blood.V110.11.3606.3606

Published: 2007

Journal Articles

Factors That Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival.

James R. Berenson, MD, Ori Yellin, MD, John Crowley, PhD, Herbert Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 4842.

https://doi.org/10.1182/blood.V110.11.4842.4842

Published: 2007

Journal Articles

Phase I Study of Bortezomib and 153 Sm-Lexidronam Combination for Refractory and Relapsed Multiple Myeloma.

James R. Berenson, MD, Regina A. Swift, Russell Mapes, Christina D. Abaya

Blood (2006) 108 (11): 3544.

https://doi.org/10.1182/blood.V108.11.3544.3544

Published: 2006

Journal Articles

The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.

James R. Berenson, Pierre Major, Regina A. Swift, Robert Vescio, Christina Rivera, Sanela Bilic, Sonia Gauron, Jannick Denouel, Horst Schran

Blood (2005) 106 (11): 5192.

https://doi.org/10.1182/blood.V106.11.5192.5192

Published: 2005

Journal Articles

Serum Pleiotrophin Is a New Multiple Myeloma Tumor Marker That Also Predicts Clinical Status.

Howard S. Yeh, MD, Haiming Chen, MD, PhD, Steven J. Manyak, Regina A. Swift, RN, Richard A. Campbell, Cathy Wang, Mingjie Li, Hee Jin, Lee, Melinda S. Gordon, PhD, Benjamin Bonavida, PhD, James R. Berenson, MD

Blood (2005) 106 (11): 3417.

https://doi.org/10.1182/blood.V106.11.3417.3417

Published: 2005

NARROW

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

Serum B-Cell Maturation Antigen Is a Novel Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival

Lack of Significance of ISS Staging and Depth of Response in Predicting Overall Survival for Multiple Myeloma Patients

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)

A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).

A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients with Previously Untreated Multiple Myeloma (MM).

A Randomized Trial Evaluating a New Powered Bone Marrow Aspirate and Core Biopsy System Compared to Traditional Manual Devices.

Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

Factors That Determine Overall Survival among Patients (Pts) with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZOL): Lack of Skeletal-Related Events (SREs) and Occurrence of Osteonecrosis of the Jaw (ONJ) Predict Improved Survival.

Phase I Study of Bortezomib and 153 Sm-Lexidronam Combination for Refractory and Relapsed Multiple Myeloma.

The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.

Serum Pleiotrophin Is a New Multiple Myeloma Tumor Marker That Also Predicts Clinical Status.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only